Hologic Inc
HOLX
ISIN null / Valor 939263
Hologic Inc
UMushroom community rating:
About company
Hologic Inc. is a global medical technology company primarily focused on improving women's health through the development and supply of innovative diagnostic products, medical imaging systems, and surgical products. The company is renowned for its advanced technologies in areas such as breast health, diagnostics, gynecological surgical solutions, and skeletal health. Hologic's product portfolio includes mammography systems, breast biopsy devices, and diagnostic tests for various health conditions, including sexually transmitted infections and cervical cancer. By leveraging its expertise in medical technology, Hologic aims to enhance patient care and outcomes, particularly in women's health, while also addressing the needs of underserved populations through initiatives like Project Health Equity.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (11.11.2025):
Hologic Inc reported its financial results for the third quarter of fiscal 2025, with revenue reaching $1,023.8 million, surpassing its guidance. The company achieved GAAP diluted EPS of $0.86 and non-GAAP diluted EPS of $1.08, both exceeding forecast ranges. Key segments showed mixed organic performance while the company maintained robust cash flow and successfully refinanced its credit facilities.
Strong Revenue Performance
The quarter recorded revenue of $1,023.8 million, exceeding the early May guidance range of $1,000 to $1,010 million, demonstrating overall growth despite a slight organic decline when excluding certain business segments.
EPS Results Above Guidance
Hologic reported GAAP diluted EPS of $0.86 and non-GAAP diluted EPS of $1.08, with non-GAAP results surpassing the high-end of the guidance range ($1.04–$1.07). This EPS performance reflects an improvement in profitability compared to previous periods.
Segment Performance Insights
The Diagnostics segment, driven by molecular diagnostics sales, experienced modest growth, while the Breast Health segment saw a decline due to reduced mammography equipment sales. In contrast, Surgical revenue grew notably, bolstered by the contributions from the acquired Gynesonics business and strong international sales.
Robust Cash Flow and Strategic Financing
The company generated a strong $343.2 million in cash flow from operations during the quarter and refinanced its debt in July, securing a $1.17 billion term loan and a $1.25 billion revolver maturing in July 2030, positioning it well for future growth and operational stability.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
16490 M
Market cap (USD)
4,530,192
Daily traded volume (Shares)
72.59 / 71.33
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
